General Information

AMP 2017 Molecular Genetic Pathology Review Course
June 1-4, 2017
DoubleTree by Hilton Hotel
Bethesda - Washington DC

AMP 2017 Molecular Genetic Pathology Review Course

Continuing Education

 

AMA PRA Category 1 Credit(s) TM

This activity was planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society for Clinical Pathology (ASCP) and the Association for Molecular Pathology. ASCP is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this LIVE educational activity for a maximum of 26 AMA PRA Category 1 Credit(s) TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

 

 

SAM Credit:

The AMP 2017 MGP Review Course is approved by the American Board of Pathology for up to 15.25 SAM credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).

COURSE OBJECTIVES*
The objectives of the AMP 2017 MGP Review Course are:

  • to assist attendees' preparation for the MGP Subspecialty Certification Exam (offered jointly by the American Board of Pathology and the American Board of Medical Genetics) as well as other certification exams in molecular pathology and molecular genetics, and
  • to increase basic and applied pathology knowledge, focusing on the molecular pathogenesis, diagnosis, prognosis and treatment of disease.

The AMP 2017 MGP Review Course will be designed to meet the participants' education needs in the physician competency area of Medical Knowledge, as defined by the Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS), and to support participants' lifelong learning towards a goal of promoting patient safety and improving patient care. At the completion of this activity, participants should be able to discuss the research underway and/or current molecular approaches to the diagnosis and prognosis of inherited diseases (including Bayesian calculations, pharmacogenetics), molecular hematopathology (including clonality, translocations, and point mutations), cytogenetics, solid and soft tissue tumors, and molecular genetic testing of infectious diseases (including bacterial, fungal, viral, and parasitic pathogens) as well as DNA identity.

TARGET AUDIENCE
The AMP 2017 MGP Review Course is especially targeted to pathologists, geneticists, technical laboratory directors, molecular pathology laboratory personnel, and trainees who:

  • plan to take a molecular diagnostics certification exam in 2017 or 2018;
  • want to obtain the molecular pathology expertise needed in today's pathology practice;
  • want to understand regulations that govern the development and use of molecular genetic tests for the safety of patients and research subjects; and/or
  • want to gain a basic and/or advanced understanding of diagnostic, prognostic, and therapeutic approaches in the areas of hematopathology (leukemias, lymphomas, lymphoproliferative disorders), solid tumors and soft tissue tumors, infectious diseases (viral, bacterial, fungal, parasitic), and inherited diseases, with the goal of improving patient care and enabling constructive interactions with pathologists, other health care practitioners, and laboratory directors and technologists.

 

* DISCLAIMER: AMP makes no guarantee or assurances that completion of its courses or participation in any educational activity will in any manner ensure a passing score on any certification examination or activity post-test, or achievement of certification status. The AMP Molecular Genetic Pathology review course is an educational program provided by the Association for Molecular Pathology, (AMP) and is not sponsored or endorsed by the American Board of Pathology (ABP) or the American Board of Medical Genetics (ABMG).